SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hunter, M. G. Articles by Avalos, B. R. Search for Related Content PubMed PubMed Citation Articles by Hunter, M. G. Articles by Avalos, B. R. Related Collections Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 95 No. 6 (March 15), 2000: pp. 2132-2137 NEOPLASIA Granulocyte colony-stimulating factor receptor mutations in severe congenital neutropenia transforming to acute myelogenous leukemia confer resistance to apoptosis and enhance cell survival Melissa G. Hunter and Belinda R. Avalos From the Molecular, Cellular, and Developmental Biology Program and the Bone Marrow Transplantation Program, The Ohio State University, Arthur G. James Cancer Hospital & Research Institute, Columbus, OH.     Abstract Top Abstract Introduction Materials and methods Results Discussion References Patients with severe congenital neutropenia (SCN) are at increased risk for the development of acute myelogenous leukemia (AML). In the subset of patients with SCN that progresses to AML, acquired mutations in the receptor for granulocyte colony-stimulating factor (G-CSF) have been detected that result in the expression of truncated forms of the G-CSF receptor (G-CSFR) protein. G-CSFR truncation mutants from these patients trans-duce hyperproliferative growth responses. In this paper, we show that the most frequently isolated mutant G-CSFR form from patients with SCN/AML (716) confers resistance to apoptosis and prolongs cell survival through a mechanism involving Akt, a downstream target of PI3-kinase. G-CSF stimulation of cells expressing the G-CSFR truncation mutant induces sustained activation of Akt and prolonged phosphorylation of the pro-apoptotic protein Bad, resulting in enhanced cell survival. Extension of cell survival allowing for sufficient time for the acquisition of additional oncogenic events may represent an important mechanism by which G-CSFR mutations contribute to leukemogenesis. These data provide further insight into the pathophysiologic contribution of G-CSFR mutations to AML. (Blood. 2000;95:2132-2137) © 2000 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results Discussion References Granulocyte colony-stimulating factor (G-CSF) is the major cytokine that drives granulopoiesis in humans and animals.1 G-CSF supports proliferation and neutrophilic differentiation of hematopoietic progenitor cells, as well as their survival. The signaling molecules activated by the G-CSF receptor (G-CSFR) to promote cell survival remain largely unknown. We previously reported that PI3-kinase is activated in response to G-CSF and that its activation correlates with inhibition of apoptosis.2 The downstream targets of PI3-kinase in the G-CSF signaling cascade that mediate cell survival have not yet been elucidated. The biologic activities of G-CSF are mediated by specific receptors on the surface of responsive cells.3,4 Recently, mutations in the G-CSFR gene resulting in truncation of the carboxy-terminal region have been detected in a subset of patients with severe congenital neutropenia (SCN) transforming to acute myelogenous leukemia (AML).5,6 Mutations in the G-CSFR in patients with SCN/AML have been found to localize to a critical cytoplasmic region spanning nucleotides 2384-2429 of the G-CSFR. These mutations, which have been detected in cells of the myeloid lineage only, have all been nonsense mutations leading to truncation of the distal cytoplasmic region of the G-CSFR and rendering cells hypersensitive to G-CSF. In the cases studied, the mutations were found to be acquired, suggesting that disruption of the normal signaling functions of the G-CSFR may contribute to leukemogenesis. Mice carrying a targeted "knock in" mutation in their G-CSFR that reproduces the most commonly found G-CSFR mutation in patients with AML preceded by SCN have been generated as an in vivo model system for studying the role of G-CSFR mutations in the pathogenesis of SCN/AML.7-9 Notably, these mice have not been found to develop AML and do not exhibit the SCN phenotype with severe neutropenia and a block in myeloid maturation. However, as in humans, an increased proliferative response to G-CSF has been observed with cells from the mutant mice. The observation that mice carrying targeted G-CSFR mutations do not develop AML implicates a requirement for additional oncogenic events. To better understand the mechanisms by which G-CSFR mutations contribute to leukemogenesis, we investigated the signaling pathways activated by the G-CSFR to promote cell growth and survival. In this article, we have identified Akt and Bad as downstream targets of PI3-kinase that promote cell survival by G-CSF. We show that mutations in the G-CSFR in SCN/AML transduce signals for increased resistance to apoptosis and enhanced cell survival, which are mediated by sustained activation of Akt and Bad. Our data suggest a mechanism whereby extension of cell survival to permit the acquisition of additional oncogenic events could underlie the development of AML in patients with antecedent SCN.     Materials and methods Top Abstract Introduction Materials and methods Results Discussion References Reagents Recombinant human G-CSF was a kind gift from Amgen (Thousand Oaks, CA). Reagents for maintenance of cell lines were purchased from GIBCO-BRL (Grand Island, NY). 32P-ATP (3000 Ci/mmol) was obtained from Amersham (Piscataway, NJ). All other reagents were obtained from Sigma (St. Louis, MO), unless otherwise indicated. Antibodies The 4G10 anti-phosphotyrosine antibody was a generous gift from Dr Brian Druker (Oregon Health Sciences University, Portland, OR). The sheep anti-Akt1 and rabbit anti-14-3-3 antibodies were obtained from Upstate Biotechnology, Inc (Lake Placid, NY). Antibodies recognizing the S and T (single-letter amino acid code) phosphorylated forms of Akt were purchased from New England Biolabs (Beverly, MA). Monoclonal antibody to Bad was obtained from Transduction Laboratories (Lexington, KY). Secondary antibodies conjugated to horseradish peroxidase were from Amersham and Kirkegaard & Perry Laboratories (Gaithersburg, MD). Cells Parental Ba/F3 cells and Ba/F3 cells transfected with the wild-type (WT) or 716 cDNAs were maintained in RPMI 1640 medium with 2 mmol/L glutamine, 10% fetal bovine serum (FBS), and 10% WEHI-3-conditioned media (WEHI-CM) as a source of interleukin-3 (IL-3). Details for the generation of Ba/F3 cells stably expressing the WT or the 716 G-CSFR form have been described previously.2 Proliferation studies Cells were washed in phosphate-buffered saline (PBS) and resuspended at 1 × 105 cells/mL in RPMI 1640 medium containing 10% FBS, 2 mmol/L glutamine, and either 10% WEHI-CM or 1.9 ng/mL G-CSF. The cells were cultured in liquid suspension at 37°C in a humidified incubator with 5% CO2. Analysis of apoptosis Cells were grown in RPMI 1640 containing 10% FBS and either 10% WEHI-CM or 1.9 ng/mL G-CSF for 10 days. The cells were washed, resuspended in medium devoid of cytokines, and incubated at 37°C. At varying times (0-72 hours), cells were removed from culture for analysis of apoptosis using the TUNEL assay. For the TUNEL assay, cells (1 × 105) were fixed in 4% formaldehyde, spun onto glass slides, subjected to the TUNEL reaction (Calbiochem, San Diego, CA) according to the manufacturer's instructions, and counterstained with methyl green. The cells were then analyzed by light microscopy. Cells in which the nuclei stained brown were scored as positive for apoptosis. Data were expressed as the percentage of negative apoptotic cells from a 200-cell count. Immunoprecipitations and Western blot analyses Cells were serum- and cytokine-deprived for 4 hours at 37°C in RPMI 1640 medium containing 0.1% bovine serum albumin and 2 mmol/L glutamine, then stimulated with 100 ng/mL G-CSF for the indicated times, and lysed in buffer A containing 1% Nonidet P-40 (Boehringer Mannheim Biochemical, Indianapolis, IN), 1 mmol/L EDTA (pH 8.0), 20 mmol/L Tris (pH 8.0), 150 mmol/L NaCl, 0.15 U/mL aprotinin, 10 µg/mL leupeptin, 10 µg/mL pepstatin A, 1 mmol/L sodium orthovanadate, and 1 µmol/L microcystin. Protein determinations of whole-cell lysates cleared of insoluble material were performed using the BCA assay (Pierce, Rockford, IL). For immunoprecipitations, 1 mg of protein was precleared with protein G-agarose (GIBCO) before immunoprecipitation with the relevant antibody. Samples stimulated with 50 µmol/L peroxyvanadate served as positive controls for activation of Akt. Western blotting was performed as described previously using enhanced chemiluminescence (ECL).2 Akt kinase assay Akt kinase assays were performed as described previously.10,11 Briefly, whole-cell lysates were immunoprecipitated at 4°C with 4 µg of anti-Akt1 conjugated to protein G-agarose. Immune complexes were washed 4 times in buffer A containing 500 mmol/L NaCl, then washed twice in kinase assay buffer containing 20 mmol/L MOPS (pH 7.2), 25 mmol/L sodium glycerophosphate, 1 mmol/L sodium orthovanadate, and 1 mmol/L dithiothreitol. The immune complexes were resuspended in kinase buffer containing 500 µmol/L ATP, 75 mmol/L MgCl2, 1 µCi 32P-ATP, and 10 µg histone H2B (Boehringer Mannheim Biochemical), and incubated for 20 minutes at 30°C. The reactions were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 15% acrylamide gel. Phosphorylation of histone H2B was quantified with a PhosphorImager (Molecular Dynamics, Sunnyvale, CA) using ImageQuant software.     Results Top Abstract Introduction Materials and methods Results Discussion References Growth characteristics of G-CSFR transfectants We previously reported that cells expressing the 716 G-CSFR were hypersensitive to G-CSF.12 We performed studies to further characterize the abnormal growth response of cells expressing this G-CSFR form, which reproduces the most frequently isolated mutant G-CSFR form from patients with SCN/AML. IL-3-dependent Ba/F3 cells transfected with either the WT or 716 G-CSFR form were grown in liquid-suspension cultures in media containing either 10% WEHI-CM (as a source of IL-3) or 1.9 ng/mL G-CSF. Growth of the cells was examined at various times over 1 month. Notably, 716 cells cultured in G-CSF-containing media grew as large cell clusters, which were apparent within 4 days after transfer of the cells to G-CSF-containing media (Figure 1). The unusual growth characteristics of 716 cells in the presence of G-CSF were observed in more than 10 independent experiments. Although the growth properties of G-CSF-expanded 716 cells suggested a transformed phenotype, these cells did not become growth factor-independent and continued to require either IL-3 or G-CSF for long-term growth (data not shown). In contrast, WT transfectants grown in either IL-3 or G-CSF and 716 transfectants grown in IL-3 grew as single-cell suspensions without the formation of large cell clusters. View larger version (9289K): [in this window] [in a new window]   Fig 1. Enhanced proliferation and cluster formation of 716 cells grown in G-CSF. Ba/F3 cells transfected with the wild-type (WT) (A, B) or 716 G-CSFR (C, D) were grown for 4 days in RPMI 1640 + 10% FBS containing either 10% WEHI-CM as a source of IL-3 (A, C) or 1.9 ng/mL G-CSF (B, D). Cells were examined by inverted microscopy at 200 × and photographed. G-CSF enhances the survival of 716 cells We next examined the survival of WT and 716 cells following growth factor deprivation. IL-3-dependent Ba/F3 cells transfected with the WT G-CSFR and grown in either G-CSF- or IL-3-containing media ceased proliferation and died within 48 hours after growth factor withdrawal (Figure 2). In contrast, Ba/F3 cells transfected with the 716 G-CSFR and grown in G-CSF-containing media showed prolonged survival and continued to proliferate for 48 hours after G-CSF withdrawal. Similar to WT transfectants grown in IL-3, 716 transfectants grown in IL-3 and subsequently deprived of IL-3 failed to proliferate and died within 48 hours. The prolonged survival of G-CSF-cultured 716 cells after growth factor deprivation was independent of the presence of serum and only partially abrogated by removal of serum from the culture medium (data not shown). View larger version (1717K): [in this window] [in a new window]   Fig 2. G-CSF pretreatment enhances the survival and proliferation of 716 cells following growth factor withdrawal. Ba/F3 cells transfected with either the WT or the 716 G-CSFR were grown in media containing either 10% WEHI-CM (source of IL-3) or 1.9 ng/mL G-CSF. The cells were washed twice and then resuspended in RPMI 1640 containing 10% FBS and 2 mmol/L glutamine with no added cytokine. At the indicated times, cells were stained with trypan blue and cell number (A) and percent viability (B) were determined. SDs were calculated from 3 independent experiments. We next investigated the mechanisms responsible for G-CSF-mediated enhanced growth and survival of 716 cells. Using the TUNEL assay to assess apoptotic cells, we observed that 716 cells were more resistant to apoptosis than WT cells after G-CSF withdrawal. As shown in Figure 3, IL-3 withdrawal induced comparable levels of apoptosis in WT and 716 transfectants. However, a striking difference in the numbers of apoptotic cells was observed between WT and 716 cells after G-CSF withdrawal. At 24 hours, only 60% of 716 cells were apoptotic, compared with approximately 97% of WT cells. At 48 hours after withdrawal from G-CSF, 22% of 716 cells still had not undergone apoptosis, but by 72 hours no viable cells were detected (data not shown). View larger version (20K): [in this window] [in a new window]   Fig 3. 716 cells are resistant to apoptosis induction following culture in G-CSF. Ba/F3 cells transfected with the WT or 716 G-CSFR were grown in RPMI 1640 medium containing 10% FBS and 2 mmol/L glutamine, supplemented with either 10% WEHI-CM (IL-3 source) or 1.9 ng/mL G-CSF. At time 0, the cells were washed, resuspended in media without added cytokine, and incubated at 37°C. At the indicated times, cells (1 × 105) were subjected to the TUNEL reaction and analyzed by light microscopy, as described in "Materials and methods." Data are expressed as the percentage of non-apoptotic cells (negative for TUNEL reaction) in a 200-cell count from 2 independent experiments. G-CSF induces sustained cellular activation in cells expressing the 716 G-CSFR mutant The selective growth and survival advantage imparted by G-CSF to 716 transfectants upon withdrawal of G-CSF and the failure to observe this in 716 transfectants following culture in IL-3 excluded an autocrine-mediated mechanism for enhanced cell survival and proliferation and supported a mechanism involving sustained activation of signaling pathways triggered by G-CSF in 716 cells. Studies were therefore done to examine intracellular signaling in G-CSF-stimulated WT and 716 cells. G-CSF rapidly induced tyrosine phosphorylation of multiple cellular proteins in both WT and 716 cells (Figure 4). Tyrosine phosphorylation was transient and by 60 minutes was no longer apparent in WT cells stimulated with G-CSF (Figure 4A). In contrast, G-CSF-induced tyrosine phosphorylation of the majority of substrates in 716 cells was still apparent at 60 minutes (Figure 4B). View larger version (57545967K): [in this window] [in a new window]   Fig 4. Sustained activation of 716 cells in response to G-CSF. Ba/F3 cells were transfected with the WT (A, C) or 716 G-CSFR (B, D). In (A) and (B), cells were serum- and cytokine-deprived and then stimulated with 100 ng/mL G-CSF for the indicated times. In (C) and (D), cells continuously growing in G-CSF-containing media were subsequently transferred to media devoid of all cytokines and analyzed at the indicated times. Whole-cell lysates were immunoblotted with the 4G10 anti-phosphotyrosine antibody. Arrows indicate proteins with prolonged tyrosine phosphorylation in 716 cells. We next examined dephosphorylation of tyrosine phosphorylated proteins in WT and 716 cells. Following removal from G-CSF-containing media, a significant reduction in the state of tyrosine phosphorylation of all proteins in WT cells was apparent within 4 hours, with a return to basal levels of phosphorylation in all proteins by 12 hours (Figure 4C). In contrast, the majority of tyrosine phosphorylated proteins activated in response to G-CSF in 716 cells could still be strongly detected at 12 hours (Figure 4D). Sustained activation of Akt in 716 cells Because we previously reported that activation of PI3-kinase by G-CSF correlates with inhibition of apoptosis,2 we investigated whether G-CSF also induced activation of the S/T anti-apoptotic kinase Akt, which is a downstream target of PI3-kinase.13-15 As shown in Figure 5, G-CSF induced phosphorylation of Akt at T308 and S473 in both WT and 716 cells. Phosphorylation of Akt was found to correlate with activation of its enzymatic activity (Figure 6). Notably, activation of the enzymatic activity of Akt in response to G-CSF was prolonged in 716 cells compared with WT cells. In 4 independent experiments, we consistently observed prolonged activation of Akt in response to G-CSF in 716 cells. Activation of Akt in WT cells was rapid and transient, with maximal activation apparent within 5 minutes and inactivation by 30 minutes. In contrast, a markedly increased level of activation of Akt was observed in response to G-CSF stimulation in 716 cells compared with WT cells, with maximal activation at 30 minutes and persistent kinase activity still apparent at 3 hours. View larger version (41K): [in this window] [in a new window]   Fig 5. Induction of S and T phosphorylation of Akt by G-CSF. Parental Ba/F3 cells or Ba/F3 cells transfected with the WT G-CSFR or the 716 G-CSFR were untreated (0) or stimulated with 100 ng/mL G-CSF (+) for 10 minutes, then lysed and immunoprecipitated with anti-Akt antibody. (A) Immunoblotting with anti-phospho-Akt (S473). (B) The blot in (A) was stripped and reblotted with antibody recognizing Akt phosphorylated at T308. (C) The blot in (B) was stripped and reblotted with anti-Akt to assess for equivalent protein loading. Arrows indicate the phosphorylated forms of Akt. Peroxyvanadate (pVO4)-stimulated 716 cells are shown as a positive control. 716 cells immunoprecipitated with normal sheep serum (IgG) instead of anti-Akt antibody represent a negative control. View larger version (19K): [in this window] [in a new window]   Fig 6. Sustained activation of Akt in 716 cells in response to G-CSF. Ba/F3 cells transfected with the WT or 716 G-CSFR were serum- and cytokine-deprived for 4 hours. The cells were stimulated with 100 ng/mL G-CSF for the indicated times, then lysed and immunoprecipitated with anti-Akt1. The immune complexes were washed and incubated in kinase buffer containing 500 µmol/L ATP, 75 mmol/L MgCl2, 1 µCi of 32PATP, and 10 µg histone H2B for 20 minutes at 30°C. The reactions were subjected to SDS-PAGE. Phosphorylation of histone H2B was quantified with a PhosphorImager using ImageQuant software. (A) Akt activity was measured as the fold-increase in histone H2B phosphorylation over unstimulated samples. Inset is a linear representation of the data. (B) Detection of histone H2B phosphorylation from samples in (A). We next examined the time course for extinction of G-CSF-induced Akt activation in WT and 716 cells upon withdrawal of the cells from G-CSF-containing media and transfer to media devoid of growth factors. Extinction of G-CSF-induced Akt activation was observed to be delayed in 716 cells. As shown in Figure 7, a decrease in the enzymatic activity of Akt was readily apparent by 2 hours after growth factor withdrawal in WT cells grown in G-CSF or IL-3 (data not shown) or in 716 cells grown in IL-3 and subsequently deprived of IL-3. In contrast, no reduction in the kinase activity of Akt was apparent in G-CSF-cultured 716 cells at 2 hours after transfer to media devoid of all cytokines, and only a minimal reduction in activity was observed at 4 hours. These results suggest that sustained activation of Akt contributes to enhanced survival of 716 cells. View larger version (18K): [in this window] [in a new window]   Fig 7. Delayed extinction of G-CSF-induced Akt activation in 716 cells. Ba/F3 cells transfected with the 716 G-CSFR were grown in RPMI 1640 medium containing 10% FBS and 2 mmol/L glutamine, supplemented with either 10% WEHI-CM (source of IL-3) or 1.9 ng/mL G-CSF for 10 days. The cells were washed twice, then transferred to media devoid of serum and cytokines. At the indicated time points, the cells were lysed, immunoprecipitated with anti-Akt, and subjected to Akt in vitro kinase assays. Data are expressed as the ratio of histone H2B phosphorylation in Akt immunoprecipitates compared with control lysates immunoprecipitated with normal sheep IgG. A linear representation of the data is shown in the inset. Phosphorylation and cytosolic sequestration of Bad are prolonged in response to G-CSF stimulation in 716 cells We investigated the downstream targets of Akt that are activated by G-CSF to induce prolonged anti-apoptotic signaling and enhanced survival of 716 cells. In response to G-CSF, Bad was phosphorylated in 716 cells, as indicated by the upward shift in its migration after G-CSF stimulation (Figure 8). Phosphorylation of Bad correlated with the time course for induction of Akt activation in 716 cells in response to G-CSF (Figure 6). Maximal phosphorylation of Bad was observed at 30 minutes, at a time when Akt activation was also maximal in 716 cells. Similar to Akt activation, the phosphorylation of Bad was also prolonged in 716 cells, with phosphorylated Bad protein still detectable several hours after G-CSF stimulation. Phosphorylated Bad was also found to associate with 14-3-3 in 716 cells after G-CSF stimulation, suggesting that Bad was sequestered in the cytosol by 14-3-3 (Figure 8B). Sequestration of Bad in the cytosol should inhibit its binding to Bcl-2 and Bcl-xL, hence promoting cell survival. View larger version (30K): [in this window] [in a new window]   Fig 8. G-CSF stimulation induces phosphorylation and cytosolic sequestration of Bad in 716 cells. Ba/F3 cells transfected with the 716 G-CSFR were serum- and cytokine-deprived for 4 hours, then stimulated with 100 ng/mL G-CSF for the indicated times and lysed. (A) Whole-cell lysates were resolved by SDS-PAGE and transferred to nitrocellulose for blotting with mouse anti-Bad. Phosphorylated Bad is indicated by an upward shift in mobility (upper tick mark) compared with unphosphorylated Bad (lower tick mark). (B) Whole-cell lysates were immunoprecipitated with anti-Bad monoclonal antibody or (C) an irrelevant antibody (anti-G-CSFR) and blotted with a rabbit polyclonal antibody to 14-3-3.     Discussion Top Abstract Introduction Materials and methods Results Discussion References Patients with SCN are at increased risk for the development of AML. In recent studies of 78 SCN patients, 8 of 9 patients who developed AML were found to have acquired mutations in the G-CSFR gene.9 Ectopic expression of G-CSFR truncation mutants from these patients in both myeloid and lymphoid cell lines has been shown to render cells hyperproliferative to G-CSF.6,12 Notably, mice carrying targeted "knock-in" mutations in the G-CSFR similar to patients with SCN/AML do not develop AML but have been found to have hyperproliferative myeloid progenitors.7-9 In response to G-CSF treatment in vivo, the mutant mice developed peripheral neutrophil counts that significantly exceeded those in mice not carrying the G-CSFR mutation. The absolute numbers of G-CSF-responsive progenitors in the bone marrow of the mutant mice were increased, and these progenitors exhibited increased proliferative responses to G-CSF. CFU-G colonies from the mutant mice were also found to be larger and showed fewer signs of degeneration. The observation that CFU-G colonies from the mutant mice showed less degeneration than those from wild-type mice suggests a defect in the induction of apoptosis in progenitor cells from the mutant mice. We previously reported that PI3-kinase is activated in response to G-CSF and that its activation promotes cell survival.2 PI3-kinase is a heterodimeric lipid kinase composed of an 85-kd regulatory subunit and a 110-kd catalytic subunit.16,17 PI3-kinase phosphorylates the 3'-position of the inositol ring on phosphoinositides and generates phosphatidylinositol 3,4-bisphosphate (PtdIns3,4P2) as well as phosphatidylinositol 3,4,5-trisphosphate (PtdIns3,4,5P3). Recently, the S/T kinase Akt was identified as a downstream target of PI3-kinase.13-15,18 The phospholipid product PtdIns3,4,5P3 generated from PI3-kinase activation was shown to bind to the pleckstrin homology domain of Akt and to activate Akt.18,19 Full activation has been shown to require phosphorylation of Akt on S473 and T308 and to be mediated in part by the PtdIns3,4,5P3-dependent protein kinase (PDK1). Activation of Akt has been shown to protect a variety of cell types from apoptosis.20-24 In the case of IL-3, IL-3 stimulation was shown to induce phosphorylation of Bad, a pro-apoptotic molecule that promotes cell death in part through heterodimerization with the anti-apoptotic proteins Bcl-2 and Bcl-xL.25 Phosphorylation of Bad was shown to be mediated by Akt and to result in cytosolic sequestration of Bad by 14-3-3 proteins and inhibition of its binding to Bcl-2 and Bcl-xL.25-28 In this article, we show that anti-apoptotic signaling by the G-CSFR is mediated by the PI3-kinase/Akt pathway and that the introduction of a mutant G-CSFR, as observed in patients with SCN/AML, into transfected cell lines disrupts this pathway to prolong cell survival. Our data with G-CSF support a model similar to that previously reported for IL-3 as well as for IL-2, platelet-derived growth factor, insulin-like growth factor-1, and fibroblast growth factor,20-25 whereby growth factor stimulation activates the PI3-kinase/Akt pathway and induces phosphorylation of Bad. In the case of SCN/AML, activation of Akt and phosphorylation of Bad in response to G-CSF are prolonged, leading to an extension in cell survival. Aberrations in apoptotic signaling pathways have been shown previously to contribute to myeloid transformation. Targeted disruption of Fas in mice was shown to result in marked increases in granulocyte progenitors despite normal steady-state granulopoiesis. However, Fas-deficient mice generated to constitutively express Bcl-2 that was targeted specifically to myeloid cells were found to develop a fatal disease analogous to human AML-M2.29 As in the case of Fas-deficient mice, which have been shown to require constitutive expression of Bcl-2 as a second "hit" for myeloid transformation,29 studies in mice with targeted G-CSFR mutations also suggest a requirement for a second "hit" for leukemic progression. The data presented here support a model whereby G-CSFR mutations in SCN/AML prolong cell survival to permit sufficient time for the acquisition of additional oncogenic events, which together induce myeloid transformation.     Acknowledgment We thank Norma Haas for her assistance in the preparation of the manuscript.     Footnotes Submitted July 21, 1999; accepted November 23, 1999. Supported by National Cancer Institute grant CA75226. Reprints: Belinda R. Avalos, The Ohio State University Bone Marrow Transplantation Program, A437A Starling-Loving Hall, 320 W Tenth Ave, Columbus, OH 43210; e-mail: avalos-1{at}medctr.osu.edu. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.     References Top Abstract Introduction Materials and methods Results Discussion References 1. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood. 1991;78:2791[Free Full Text]. 2. Hunter MG, Avalos BR. Phosphatidylinositol 3'-kinase and SH2-containing inositol phosphatase (SHIP) are recruited by distinct positive and negative growth-regulatory domains in the granulocyte colony-stimulating factor receptor. J Immunol. 1998;160:4979[Abstract/Free Full Text]. 3. Begley CG, Metcalf D, Nicola NA. Binding characteristics and proliferative action of purified granulocyte-colony stimulating factor (G-CSF) on normal and leukemic human promyelocytes. Exp Hematol. 1988;16:71[Medline] [Order article via Infotrieve]. 4. Nicola NA, Metcalf D. Binding of 125I-labeled granulocyte colony-stimulating factor to normal murine hemopoietic cells. J Cell Physiol. 1985;124:313[Medline] [Order article via Infotrieve]. 5. Dong F, Hoefsloot LH, Schelen AM, et al. Identification of a nonsense mutation in the granulocyte colony-stimulating factor in severe congenital neutropenia. Proc Natl Acad Sci U S A. 1994;91:4480[Abstract/Free Full Text]. 6. Dong F, Brynes RK, Tidow N, Welte K, Löwenberg B, Touw IP. Mutations in the gene for the granulocyte colony-stimulating-factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med. 1995;333:487[Abstract/Free Full Text]. 7. McLemore M, Poursine-Laurent J, Link DC. Increased granulocyte colony-stimulating factor responsiveness but normal resting granulopoiesis in mice carrying a targeted granulocyte colony-stimulating factor receptor mutation derived from a patient with severe congenital neutropenia. J Clin Invest. 1998;102:483[Medline] [Order article via Infotrieve]. 8. Hermans MHA, Ward AC, Antonissen C, Karis A, Löwenberg B, Touw IP. Perturbed granulopoiesis in mice with a targeted mutation in the granulocyte colony-stimulating factor receptor gene associated with severe congenital neutropenia. Blood. 1998;92:32[Abstract/Free Full Text]. 9. Hermans MHA, Antonissen C, Ward AC, Mayhen AEM, Ploemacher RE, Touw IP. Sustained receptor activation and hyperproliferation in response to granulocyte colony-stimulating factor (G-CSF) in mice with a severe congenital neutropenia/acute myeloid leukemia-derived mutation in the G-CSF receptor gene. J Exp Med. 1999;189:683[Abstract/Free Full Text]. 10. Franke TF, Sung-II Y, Chan TO, et al. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell. 1995;81:727[Medline] [Order article via Infotrieve]. 11. Scheid MP, Duronio V. Dissociation of cytokine-induced phosphorylation of Bad and activation of PKB/Akt: involvement of MEK upstream of Bad phosphorylation. Proc Natl Acad Sci U S A. 1998;95:7439[Abstract/Free Full Text]. 12. Hunter MG, Avalos BR. Deletion of a critical internalization domain in the G-CSFR in acute myelogenous leukemia preceded by severe congenital neutropenia. Blood. 1999;93:440[Abstract/Free Full Text]. 13. Stokoe D, Stephens LR, Copeland T, et al. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science. 1997;277:567[Abstract/Free Full Text]. 14. Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha. Curr Biol. 1997;7:261[Medline] [Order article via Infotrieve]. 15. Stephens L, Anderson K, Stokoe D, et al. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science. 1998;279:710[Abstract/Free Full Text]. 16. Kapeller R, Cantley LC. Phosphatidylinositol 3-kinase. Bioessays. 1994;16:565[Medline] [Order article via Infotrieve]. 17. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci. 1997;22:267[Medline] [Order article via Infotrieve]. 18. Franke TF, Kaplan DR, Cantley LC, Toker A. Direct regulation of the Akt proto-oncogene product by phosphatidylinositol-3,4-bisphosphate. Science. 1997;275:665[Abstract/Free Full Text]. 19. Frech M, Andjelkovic M, Ingley E, Reddy KK, Falck JR, Hemmings BA. High affinity binding of inositol phosphates and phosphoinositides to the pleckstrin homology domain of RAC/protein kinase B and their influence on kinase activity. J Biol Chem. 1997;272:8474[Abstract/Free Full Text]. 20. Ahmed WN, Leighton Grimes H, Bellacosa A, Chan TO, Tsichlis PN, Hay N. Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase. Proc Natl Acad Sci U S A. 1997;94:3627[Abstract/Free Full Text]. 21. Songyang Z, Baltimore D, Cantley LC, Kaplan DR, Franke T. Interleukin 3-dependent survival by the Akt protein kinase. Proc Natl Acad Sci U S A. 1997;94:11,345[Abstract/Free Full Text]. 22. Kennedy SG, Wagner AJ, Conzen SD, et al. The PI 3-kinase/Akt signaling pathway delivers an anti-apoptotic signal. Genes Dev. 1997;11:701[Abstract/Free Full Text]. 23. Kulik G, Klippel A, Weber MJ. Antiapoptotic signaling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt. Mol Cell Biol. 1997;17:1595[Abstract]. 24. Eves EM, Xiong W, Bellacosa A, et al. Akt, a target of phosphatidylinositol 3-kinase, inhibits apoptosis in a differentiating neuronal cell line. Mol Cell Biol. 1998;18:2143[Abstract/Free Full Text]. 25. DelPeso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997;278:687[Abstract/Free Full Text]. 26. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231[Medline] [Order article via Infotrieve]. 27. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-xl and Bcl-2, displaces Bax and promotes cell death. Cell. 1995;80:285[Medline] [Order article via Infotrieve]. 28. Zha J, Harada H, Yang E, Jockel J, Korsmeyer SJ. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3, not Bcl-xl. Cell. 1996;87:619[Medline] [Order article via Infotrieve]. 29. Traver D, Akashi K, Weissman IL, Lagasse E. Mice defective in two apoptosis pathways in the myeloid lineage develop acute myeloblastic leukemia. Immunity. 1998;9:47[Medline] [Order article via Infotrieve]. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: N. Berliner Lessons from congenital neutropenia: 50 years of progress in understanding myelopoiesis Blood, June 15, 2008; 111(12): 5427 - 5432. [Abstract] [Full Text] [PDF] D. C. Link, G. Kunter, Y. Kasai, Y. Zhao, T. Miner, M. D. McLellan, R. E. Ries, D. Kapur, R. Nagarajan, D. C. Dale, et al. Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia Blood, September 1, 2007; 110(5): 1648 - 1655. [Abstract] [Full Text] [PDF] M. Germeshausen, M. Ballmaier, and K. Welte Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: results of a long-term survey Blood, January 1, 2007; 109(1): 93 - 99. [Abstract] [Full Text] [PDF] E. M. Sloand, A. S. M. Yong, S. Ramkissoon, E. Solomou, T. C. Bruno, S. Kim, M. Fuhrer, S. Kajigaya, A. J. Barrett, and N. S. Young Granulocyte colony-stimulating factor preferentially stimulates proliferation of monosomy 7 cells bearing the isoform IV receptor PNAS, September 26, 2006; 103(39): 14483 - 14488. [Abstract] [Full Text] [PDF] P. S. Rosenberg, B. P. Alter, A. A. Bolyard, M. A. Bonilla, L. A. Boxer, B. Cham, C. Fier, M. Freedman, G. Kannourakis, S. Kinsey, et al. The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy Blood, June 15, 2006; 107(12): 4628 - 4635. [Abstract] [Full Text] [PDF] D. Zhuang, Y. Qiu, S. C. Kogan, and F. Dong Increased CCAAT Enhancer-binding Protein {epsilon} (C/EBP{epsilon}) Expression and Premature Apoptosis in Myeloid Cells Expressing Gfi-1 N382S Mutant Associated with Severe Congenital Neutropenia J. Biol. Chem., April 21, 2006; 281(16): 10745 - 10751. [Abstract] [Full Text] [PDF] H. Liu, Y. Qiu, L. Xiao, and F. Dong Involvement of Protein Kinase C{epsilon} in the Negative Regulation of Akt Activation Stimulated by Granulocyte Colony-Stimulating Factor J. Immunol., February 15, 2006; 176(4): 2407 - 2413. [Abstract] [Full Text] [PDF] D. Zhuang, Y. Qiu, S. J. Haque, and F. Dong Tyrosine 729 of the G-CSF receptor controls the duration of receptor signaling: involvement of SOCS3 and SOCS1 J. Leukoc. Biol., October 1, 2005; 78(4): 1008 - 1015. [Abstract] [Full Text] [PDF] M. G. Hunter, A. Jacob, L. C. O'Donnell, A. Agler, L. J. Druhan, K. M. Coggeshall, and B. R. Avalos Loss of SHIP and CIS Recruitment to the Granulocyte Colony-Stimulating Factor Receptor Contribute to Hyperproliferative Responses in Severe Congenital Neutropenia/Acute Myelogenous Leukemia J. Immunol., October 15, 2004; 173(8): 5036 - 5045. [Abstract] [Full Text] [PDF] L. H. J. Aarts, O. Roovers, A. C. Ward, and I. P. Touw Receptor activation and 2 distinct COOH-terminal motifs control G-CSF receptor distribution and internalization kinetics Blood, January 15, 2004; 103(2): 571 - 579. [Abstract] [Full Text] [PDF] J. A. Lehman, V. Calvo, and J. Gomez-Cambronero Mechanism of Ribosomal p70S6 Kinase Activation by Granulocyte Macrophage Colony-stimulating Factor in Neutrophils: COOPERATION OF A MEK-RELATED, THR421/SER424 KINASE AND A RAPAMYCIN-SENSITIVE, mTOR-RELATED THR389 KINASE J. Biol. Chem., July 18, 2003; 278(30): 28130 - 28138. [Abstract] [Full Text] [PDF] Z.-Q. Ning, J. Li, and R. J. Arceci Signal transducer and activator of transcription 3 activation is required for Asp816 mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells Blood, June 1, 2001; 97(11): 3559 - 3567. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hunter, M. G. Articles by Avalos, B. R. Search for Related Content PubMed PubMed Citation Articles by Hunter, M. G. Articles by Avalos, B. R. Related Collections Neoplasia Social Bookmarking                   What's this?

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020